Selank vs Semax: Anxiolytic and Cognitive Research Compared

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Selank and Semax are synthetic peptides discovered and developed by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences. Although they contain the same stabilizing motif and have a similar delivery mechanism, their main effects and areas of research differ greatly.

Semax has more cognitive function enhancing and neuroprotective properties. Selank is more closely associated with anxiety and stress response modulation. Knowing how these two peptides differ on a molecular level helps researchers select the right compound for their specific in vitro models.

Key Highlights

• Both peptides are synthetic heptapeptides derived from different parent molecules, sharing a Pro-Gly-Pro C-terminal extension for metabolic stability
• Semax is primarily studied for BDNF upregulation, dopaminergic signaling, and neuroprotection in cognitive and ischemic models
• Selank is more established as an anxiolytic research compound, with GABAergic gene modulation as a key mechanism
• A 2020 fMRI study identified both shared and peptide-specific effects on amygdala-temporal functional connectivity

Selank and Semax: Origins and Structure

Semax carries the sequence Met-Glu-His-Phe-Pro-Gly-Pro and is derived from ACTH(4-7), a fragment of adrenocorticotropic hormone. Despite this lineage, Semax is entirely devoid of hormonal activity. The Pro-Gly-Pro C-terminal extension was added to improve resistance to enzymatic degradation — a design feature shared with Selank.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) takes a different origin. It is a synthetic analogue of tuftsin, a tetrapeptide naturally derived from the Fc-fragment of immunoglobulin G. This immunoglobulin lineage gives Selank a distinct immunomodulatory character not seen in Semax.

Attribute	Semax	Selank
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Parent molecule	ACTH(4-7) fragment	Tuftsin (IgG-derived)
Stabilizing motif	Pro-Gly-Pro C-terminal extension	Pro-Gly-Pro C-terminal extension
Primary research focus	Cognitive enhancement, neuroprotection	Anxiolytic activity, stress modulation

Both peptides achieve rapid CNS uptake via olfactory and trigeminal pathways. Both also share the notable property of producing no sedation in experimental research models — a characteristic that distinguishes them from conventional anxiolytics and stimulants.

How Semax and Selank Peptides Work

Although both peptides impact neuroplasticity and neurotransmission, their main mechanisms of action are quite different.

Featured Products: Buy N-Acetyl Semax or N-Acetyl Selank for in vitro laboratory research applications.

Semax: Neurotrophic and Dopaminergic Activity

The centerpiece of Semax’s mechanism is robust BDNF upregulation. Semax activates the CREB transcription factor, increasing BDNF mRNA and protein levels in the hippocampus, cortex, and striatum. This triggers downstream PI3K/Akt, MAPK/ERK, and PLCγ signaling cascades linked to neuronal survival, synaptic plasticity, and neurogenesis.^[1]

Beyond BDNF, Semax research has documented:

• Increased dopamine synthesis and receptor sensitivity in the striatum and prefrontal cortex
• Elevated serotonin turnover and 5-HT1A receptor signaling
• Cholinergic pathway support associated with memory and learning models
• Anti-inflammatory activity, including upregulation of SOD, catalase, and glutathione peroxidase, and reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
• Microglial polarization toward the reparative M2 phenotype

A genome-wide transcriptomic analysis found that over 50% of Semax-affected genes relate to immune and vascular expression — particularly under ischemic conditions. This genomic signature distinguishes it from Selank at the molecular level.

Selank: GABAergic Gene Modulation

Selank’s anxiolytic profile does not arise from direct GABA receptor binding. Instead, Selank influences the expression of genes encoding GABA receptor subunits in the hippocampus and amygdala.

A study by Volkova et al. (2016) found that Selank significantly altered four genes involved in GABAergic neurotransmission — Drd1a, Drd2, Slc6a13, and Ptgs2 — with pronounced changes also observed for Gabre, Gabrq, and Hcrt. Gene expression changes correlated positively with GABA administration at 1 hour (r = 0.86; p ≤ 0.05).^[2]

Additional mechanisms documented in Selank research include:

• Serotonin concentration increases in the hippocampus, hypothalamus, and frontal cortex
• Prevention of stress-induced dopamine depletion in the striatum and nucleus accumbens
• Rapid BDNF elevation in the rat hippocampus, considered secondary to GABAergic activity
• Modulation of IL-6, T helper cytokine balance, and NK cell activity — reflecting its tuftsin ancestry
• Enhanced preproenkephalin expression, suggesting endogenous opioid pathway involvement

Mechanistic Comparison

Dimension	Semax	Selank
Parent molecule	ACTH(4-7) fragment	Tuftsin (IgG-derived)
Primary neurotransmitter targets	Dopamine, serotonin, acetylcholine	GABA (indirect), serotonin, dopamine
BDNF effect	Primary mechanism; robust upregulation	Secondary; rapid hippocampal elevation
Genomic signature	Immune and vascular gene expression	Neurotransmission genes (GABAergic)
Anti-inflammatory profile	Cytokine reduction, microglial M2 shift	Cytokine normalization, NK cell modulation
Hormonal activity	None	None

Stress and Anxiety Research Models

Selank’s Established Anxiolytic Profile

Selank has the more developed anxiolytic research record of the two. In preclinical models using the elevated plus maze (EPM), Selank administration significantly increased time spent in open arms and open arm entries, with anxiolytic effects comparable to diazepam but without sedation or motor impairment. Similar patterns were observed in light-dark box, conditioned fear, chronic restraint stress, and social defeat paradigms.^[3]

On the clinical side, a randomized controlled trial in 60 participants with generalized anxiety disorder found that Selank significantly reduced Hamilton Anxiety Rating Scale (HAM-A) scores versus placebo. Effects were measurable by day 7 and maximal by day 14, with no sedation, cognitive impairment, or motor coordination deficits observed.^[4]

A separate trial by Zozulia et al. enrolled 62 participants across GAD and neurasthenia cohorts. Selank showed effects comparable to medazepam, with additional positive outcomes in neurasthenic symptom reduction and noted psychostimulant-like activity.^[5]

A response pattern analysis identified two distinct responder groups. Approximately 40% of participants showed abrupt symptom reduction within 1–3 days (HAM-A dropping from 20.3 to 7.0, p < 0.01). The remaining 60% responded gradually, reaching significance by day 14 (HAM-A from 16.1 to 6.2, p < 0.01). Rapid responders demonstrated higher EEG reactivity after a single dose, with increased beta-rhythm and decreased theta/low-alpha activity — suggesting potential EEG-based responder stratification.^[4]

Semax’s Secondary Stress-Modulating Activity

Semax is not classified primarily as an anxiolytic, but it does modulate stress response pathways in ways relevant to anxiety-related research models.

Semax has been shown to prevent stress-induced corticosterone elevations while preserving appropriate stress reactivity, pointing to HPA axis modulation rather than suppression. BDNF upregulation also connects to long-term adaptive stress responses and neuroplasticity under chronic stress conditions.^[6]

Semax is considered less potent than Selank in direct anxiety modulation, lacking the GABAergic gene expression signature that drives Selank’s primary anxiolytic profile.

Cognitive Enhancement Research Models

Semax: Direct Neuroplasticity Enhancement

Semax consistently shows stronger results than Selank in cognitive domains including attention, learning, memory, and processing speed — particularly in stress or injury conditions.

A 2025 study using transgenic APP/PS1 Alzheimer’s disease mice found that intranasal Semax improved performance across the open field test, novel object recognition test, and Barnes maze. Histologically, Semax reduced amyloid plaque counts in the cortex by 2.8-fold and in the hippocampus by 2.6-fold compared to untreated APP/PS1 mice. These reductions persisted 1.5 months post-treatment (2.2-fold and 1.7-fold respectively), suggesting inhibition of new plaque formation rather than clearance of existing plaques.^[7]

Additional findings from the research literature include:

• Improved passive avoidance task performance in healthy rats within 15 minutes of application
• Increased plasma BDNF levels in stroke models, with high-BDNF responders showing accelerated rehabilitation timelines
• A meta-analysis of 8 studies (n = 654) finding that Semax significantly reduced stroke severity scores at 10–14 and 21 days in moderate-to-severe stroke models

An Alzheimer’s Drug Discovery Foundation review noted improved attention and short-term memory outcomes in healthy subjects alongside EEG changes consistent with other neuroprotective compounds.

Selank: Cognition Under Stress Conditions

Selank’s cognitive benefits are more context-dependent. Research shows improvements in passive avoidance, active avoidance, and Morris water maze performance, with effects most pronounced in stress conditions. Selank also enhances long-term potentiation (LTP) in hippocampal synapses in preclinical models.^[8]

In mild cognitive impairment studies, Selank improved attention, memory consolidation, and executive function. EEG studies showed increased alpha-rhythm power consistent with enhanced cognitive processing states.

The key distinction: Selank’s cognitive benefits appear primarily mediated through anxiolysis — removing the cognitive interference caused by anxiety — while Semax directly targets neuroplasticity and neurotransmission to increase cognitive capacity in these models.

Neuroimaging Evidence: Shared and Distinct Effects

A 2020 resting-state fMRI study directly compared Semax and Selank in 52 healthy participants. Scans were taken at baseline, 5 minutes, and 20 minutes post-administration.^[9]

Both peptides modulated functional connectivity (FC) between the right amygdala and the right temporal cortex, including the fusiform, inferior/middle temporal, and parahippocampal gyri. Regions of interest also included the dorsolateral prefrontal cortex (DLPFC), a key node for executive function and working memory.

The study identified both shared and peptide-specific effects on amygdala-temporal connectivity. This represents the first neuroimaging evidence that both peptides acutely modulate circuits central to anxiety regulation and cognitive control in a human research context — and provides a meaningful bridge between the preclinical and clinical literature.

Potential In Vitro Research Applications

Research Area	Relevant Peptide(s)	Model Context
Anxiety pathway and GABAergic gene expression modeling	Selank	Hippocampal and amygdala cell cultures
Neuroplasticity and BDNF signaling studies	Semax	Cortical and hippocampal neuronal cultures
HPA axis and stress response modulation	Semax, Selank	Corticotroph cell lines, stress paradigm models
Neuroinflammation and cytokine signaling	Semax	Microglial cell cultures, inflammatory cytokine assays
Immunomodulation and NK cell activity	Selank	Peripheral blood mononuclear cell (PBMC) assays
Amyloid pathology and plaque formation	Semax	Transgenic cell lines, APP/PS1 model systems
Long-term potentiation and synaptic plasticity	Selank, Semax	Ex vivo hippocampal slice preparations
Dopaminergic and serotonergic receptor modulation	Semax	Striatal and prefrontal cortex preparations

Conclusion

Semax and Selank occupy complementary positions in neuropeptide research.

Selank is the more established anxiolytic research compound, with GABAergic gene modulation as its primary mechanism and immunomodulatory properties rooted in its tuftsin lineage. The responder stratification data — with EEG reactivity correlating to early gene expression changes — adds useful context for researchers studying anxiety pathway signaling at the cellular level.

Semax is the stronger candidate for neuroplasticity and neuroprotection research, with BDNF upregulation as its central mechanism and a growing body of evidence in ischemic and neurodegenerative cell models. The 2025 amyloid plaque reduction data from transgenic mice adds a relevant dimension for researchers investigating amyloid pathology mechanisms in vitro.

Both peptides show an absence of sedative activity and no observed tolerance in study conditions — properties that make them useful tools for isolating specific pathway effects in cellular models. The primary gap across both bodies of literature remains the need for large-scale replication outside of Russian research institutions.

Researchers sourcing either compound should prioritize verified purity documentation and confirmed molecular identity before use. BioLongevity Labs supplies research-grade Semax and Selank verified to >99% purity via triple third-party testing, with full COA documentation available prior to purchase. All products are strictly for in vitro research use only.

References

1. Dolotov OV, Seredenina TS, Levitskaya NG, Kamensky AA, Andreeva LA, Alfeeva LYu, et al. The Heptapeptide SEMAX stimulates BDNF Expression in Different Areas of the Rat Brain in vivo. Springer Science and Business Media LLC; 2003. https://doi.org/10.1023/a:1025177812262
2. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers Media SA; 2016. https://doi.org/10.3389/fphar.2016.00031
3. Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Wiley; 2017. https://doi.org/10.1155/2017/5091027
4. Syunyakov T, Teleshova ES, Neznamov GG, Bochkarev VK. P-1114 – Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank. Cambridge University Press (CUP); 2012. https://doi.org/10.1016/s0924-9338(12)75281-1
5. Aa Z, Gg N, Ts S, Nv K, Gabaeva M, OIu S, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova. 2008;108(4):38–48.
6. Volodina MA, Sebentsova EA, Glazova NYu, Manchenko DM, Inozemtseva LS, Dolotov OV, et al. Correction of Long-Lasting Negative Effects of Neonatal Isolation in White Rats Using Semax. Acta Naturae Ltd; 2012. https://doi.org/10.32607/20758251-2012-4-1-86-92
7. Radchenko AI, Kuzubova EV, Apostol AA, Mitkevich VA, Andreeva LA, Limborskaya SA, et al. The potential of the peptide drug Semax and Its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae Ltd; 2025. https://doi.org/10.32607/actanaturae.27808
8. Semenova T, Kozlovskii II, Zakharova NM, Kozlovskaia MM. [Experimental optimization of learning and memory processes by selank]. Экспериментальная и клиническая фармакология. 2010;73(8):2–5.
9. Panikratova YaR, Lebedeva IS, Sokolov OYu, Rumshiskaya AD, Kupriyanov DA, Kost NV, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Pleiades Publishing Ltd; 2020. https://doi.org/10.1134/s001249662001007x